Bioinvent International AB (0H22) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Nov 2026 10:17 AM
MFN
BioInvent to Participate in Upcoming Investor...
06 Nov 2026 03:15 PM
MFN
BioInvent: Fair Value Adjusted for Rights Iss...
05 Nov 2026 10:05 PM
MFN
BioInvent announces final terms for the Right...
30 Oct 2026 04:30 PM
MFN
Supplement: Notice to Extraordinary General M...
28 Oct 2026 05:17 PM
MFN
BioInvent International AB: Interim report Ja...
28 Oct 2026 05:16 PM
MFN
Notice to Extraordinary General Meeting in Bi...
28 Oct 2026 05:15 PM
MFN
BioInvent resolves on a rights issue of appro...
24 Oct 2026 08:00 AM
MFN
BioInvent's BI-1808 and KEYTRUDA® Induce Dura...
12 Oct 2026 08:45 AM
MFN
BioInvent International AB announces that its...
27 Aug 2026 07:00 AM
MFN
BioInvent International AB: Interim report Ja...
21 May 2026 10:00 PM
MFN
BioInvent Reveals Solid Data with its TNFR2 A...
29 Apr 2026 04:30 PM
MFN
Resolutions at BioInvent’s Annual General Mee...
29 Apr 2026 07:00 AM
MFN
BioInvent International AB: Interim report Ja...
31 Mar 2026 10:45 AM
MFN
BioInvent International AB publishes Annual R...
24 Mar 2026 07:00 AM
MFN
Notice to Annual General Meeting in BioInvent...
26 Feb 2026 07:00 AM
MFN
BioInvent International AB: Year-end report J...
05 Jan 2026 06:30 AM
MFN
BioInvent Reports Promising Data from Ongoing...
08 Dec 2025 01:00 PM
MFN
BioInvent Presents Impressive Response Data f...
07 Dec 2025 01:00 PM
MFN
BioInvent Presents Promising Early Phase 2a B...
03 Nov 2025 02:00 PM
MFN
BioInvent to Present Updated Phase 2a BI-1808...
03 Nov 2025 02:00 PM
MFN
BioInvent to Present Early Phase 2a Data from...
29 Oct 2025 07:00 AM
MFN
BioInvent International AB: Interim Report Ja...
02 Sep 2025 09:10 AM
MFN
BioInvent Announces Board of Directors Update
26 Aug 2025 07:30 AM
MFN
BioInvent International AB: Interim Report Ja...
26 Aug 2025 07:29 AM
MFN
BioInvent Announces Strategic Changes in Port...
28 Jul 2025 07:30 AM
MFN
Transgene and BioInvent to Present Updated Da...

BioInvent International is a Swedish clinical-stage biopharmaceutical company that discovers and develops novel antibody-based cancer immunotherapies.

BioInvent share price is listed in London under the ticker 0H22.

UK 100

Latest directors dealings